White Papers
Our work in White Papers
-
Is the U.S. Ready to Quickly Vaccinate its Population Against COVID-19?
Once a COVID-19 vaccine is developed, achieving universal immunization will require a cohesive, multi-faceted vaccination strategy across the U.S. healthcare system.
Categorized in -
Getting Americans Back to Work (and School) With Pooled Testing
To reopen safely, employers need to identify workers who have active COVID-19 infections and do so at reasonable cost. Pooled testing for the coronavirus is an effective, scalable tool for doing so.
Categorized in -
How Well Could Tax-Based Auto-Enrollment Work?
Auto-enrollment into health insurance coverage is an attractive policy that can drive the U.S. health care system towards universal coverage.
-
How Would Sharing Rebates at the Point-Of-Sale Affect Beneficiary Cost-Sharing in Medicare Part D?
If cost-sharing were based on net price it would provide meaningful financial relief to many Part D beneficiaries.
-
Health Technology Assessment for the U.S. Healthcare System
A white paper from the USC Schaeffer Center-Aspen Institute Advisory Panel on health technology assessment in the U.S. Experts explore how to better link the price of health technologies to the benefits they provide to patients while ensuring a sustainable healthcare ecosystem that supports innovation.
Categorized in -
The Association Between Drug Rebates and List Prices
Drug rebates and list prices are positively correlated: On average, a $1 increase in rebates is associated with a $1.17 increase in list price.
Categorized in -
Georgia’s 1332 Waiver Violates the ACA and Cannot Lawfully be Approved
Christen Linke Young and Jason Levitis explain why Georgia’s 1332 waiver would fail the affordability guardrail and is based on several assumptions.
-
Hospital System Participation and Hospital Spending
Schaeffer Center researchers found that most hospital systems span across markets and states with higher system participation were more likely to have below median per capita hospital spending. Their work suggests that researchers and policymakers should consider hospital system membership separately from market concentration.
Categorized in -
State Drug Pricing Transparency Laws: Numerous Efforts, Most Fall Short
166 recently enacted prescription drug pricing laws were analyzed to identify those that contained price transparency measures. Of these, 35 bills in 22 states include a transparency component, but only 7 were deemed to be informative.
Categorized in -
Value-Based Contracting in Healthcare: What Is It and How Can It Be Achieved?
Value-based contracts must incentivize the clinical decision maker, usually the physician, to allocate treatment based on both price and value. Changing certain elements in the financing system could create an environment for successful value-based contracting without having to reform the entire system.
Categorized in